Sorry, you need to enable JavaScript to visit this website.

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

A Phase 2, Non-Randomized, Open-Label, Single-Arm, Multi-Center Study of Talazoparib for Neoadjuvant Treatment of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Category & Conditions: Cancer
Medicine: Talzenna (talazoparib)
ClinicalTrials.gov Identifier (NCT): NCT03499353
Protocol ID: C3441020
    Share
PrintDownload
Open Plain Language Summary Result: Click here